Announcements Trials
Browse Landscape

Phase

Phase 2 4

Status

Unknown 4

Sponsor Class

OTHER 57INDUSTRY 6UNKNOWN 4OTHER_GOV 3

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 4CNS 1

Conditions

Breast Neoplasms 4Carcinoma, Transitional Cell 1Brain Neoplasms 1Advanced Breast Cancer 1

Interventions

Paclitaxel 5Capecitabine 5pyrotinib 4Epirubicin 4Docetaxel 4exemestane 3Vinorelbine 3Radiotherapy 3Radiation Dose Hypofractionation 3Fulvestrant 3Carboplatin 3apatinib 2Neoadjuvant Therapy 2Letrozole 2Etoposide 2Cyclophosphamide 2Albumin-Bound Paclitaxel 2toripalimab 1titanium silicide 1pirarubicin 1palbociclib 1nimotuzumab 1icaritin 1anlotinib 1Therapeutics 1Standard of Care 1Radiation 1Pemetrexed 1Nutrition Assessment 1Methods 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
UNKNOWN × Breast Neoplasms × pyrotinib × Clear all
NCT04033172 2019-07-25

Pyrotinib

ChineseAMS

Phase 2 Unknown
40 enrolled
Breast

Breast Neoplasms

NCT03933982 2019-05-29

Pyrotinib

ChineseAMS

Phase 2 Unknown
30 enrolled
BreastCNS

Brain Neoplasms, Breast Neoplasms

NCT03923166 2019-04-22

Pyrotinib Combined With Capecitabine Metronomic Therapy in HER2-postitive Advanced Breast Cancer

ChineseAMS

Phase 2 Unknown
35 enrolled
Breast

Breast Neoplasms

NCT03923179 2019-04-22

Phase II Clinical Study of Pyrotinib Combined With Etoposide to Treat HER2-positive Advanced Breast Cancer

ChineseAMS

Phase 2 Unknown
32 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡